Prelude Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
PRLD$3.76+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows (Unaudited)
STATEMENTS OF CASH FLOWS
| Nine months ended September 30, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Cash flows used in operating activities: | ||
| Net loss | $(98,442) | $(88,757) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,283 | 838 |
| Noncash lease expense | 1,203 | 1,328 |
| Stock-based compensation | 17,571 | 19,704 |
| Amortization of premium and discount on marketable securities, net | (3,688) | (2,402) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (107) | (2,053) |
| Accounts payable | 1,495 | (1,805) |
| Accrued expenses and other liabilities | (2,375) | (1,873) |
| Long-term prepaid expenses and other long-term assets | — | (7,108) |
| Operating lease liabilities | 916 | (1,357) |
| Net cash used in operating activities | (82,144) | (83,485) |
| Cash flows provided by investing activities: | ||
| Purchases of marketable securities | (45,366) | (162,248) |
| Proceeds from maturities of marketable securities | 114,150 | 122,250 |
| Purchases of property and equipment | (711) | (2,384) |
| Net cash provided by (used in) investing activities | 68,073 | (42,382) |
| Cash flows used in financing activities: | ||
| Payment of offering costs | (110) | — |
| Proceeds from issuance of common stock and pre-funded warrants, net of offering costs | — | 110,795 |
| Proceeds from the issuance of common stock under ESPP | 255 | 348 |
| Proceeds from the issuance of common stock in connection with the exercise of stock options | 60 | 31 |
| Payment of withholding taxes related to stock-based compensation to employees | (47) | (16) |
| Principal payments on finance lease liabilities | (244) | — |
| Net cash (used in) provided by financing activities | (86) | 111,158 |
| Net decrease in cash, cash equivalents and restricted cash | (14,157) | (14,709) |
| Cash, cash equivalents, and restricted cash at beginning of period | 29,335 | 34,649 |
| Cash, cash equivalents, and restricted cash at end of period | $15,178 | $19,940 |
| Supplemental disclosures of non-cash activities: | ||
| Property and equipment in accounts payable and accrued expenses and other current liabilities | $9 | $254 |
| Offering costs in accrued expenses and other current liabilities | $— | $28 |
| Offering costs in accounts payable | $— | $34 |
| Unrealized (loss) gain on marketable securities | $(56) | $1,087 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.